Saturday 17 October 2026
Export IXHL’s income statement to Excel — free account
Incannex Healthcare Inc.
IXHL Healthcare Drug Manufacturers Specialty & Generic
Incannex Healthcare Inc.’s revenue for fiscal 2025 (year ended June 2025) was $86,000.00, up 616.7% from fiscal 2024. In the quarter to June 2026, revenue fell 92.3%, EPS grew 99.0% and free cash flow grew 327.7%, each against the same quarter a year earlier.
2.82
0.06
−2.08%
Follow IXHL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
47.21 | 47.99 | 41.35 | 48.45 | |
Current Ratio |
47.51 | 48.27 | 41.56 | 48.81 | |
Net Debt/EBITDA |
10.89 | 9.98 | 18.69 | 13.17 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.43 | 0.71 | 0.63 | (1.35) | |
Capex/Depreciation |
(0.03) | (0.07) | (0.08) | 0.02 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.89) | (0.40) | (0.20) | 0.29 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.89) | (0.40) | (0.20) | 0.29 | |
Cash per Share |
7.09 | 5.95 | 6.03 | 5.81 | |
Shareholders Equity per Share |
7.45 | 6.31 | 6.09 | 5.78 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.45 | 6.31 | 6.09 | 5.78 | |
Free Cash Flow |
(9.16) | (4.63) | (2.46) | 3.38 | |
Working Capital |
76.65 | 73.13 | 78.17 | 71.34 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
76.58 | 73.08 | 75.05 | 67.22 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.81 | 5.83 | 6.17 | 4.36 | |
Average Payables |
1.43 | 1.05 | 1.35 | 3.63 | |
Average Assets |
47.38 | 43.06 | 48.24 | 46.71 | |
Average Common Equity |
41.80 | 37.19 | 41.32 | 40.38 |
Columns are period end dates · fundamentals updated 6 Oct 2026